Aerocrine Reports Record Sales for the 4th Quarter and Full

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jan 7, 2015 at 2:15 AM

Aerocrine Reports Record Sales for the 4th Quarter and Full Year 2014

In advance of the EGM we are issuing top line results for Q4 and the full year in anticipation of the publication of the rights offering prospectus on January 12th. Our full year end results are scheduled to be published on February 20th. January – December 2014 · Net sales increased by 22% to 166 (136)* MSEK. · Net sales for clinical use of NIOX products were 129 (102)* MSEK, an increase of 26% · Strategic sales (sales to pharmaceutical companies and CROs for clinical trials) were 33 (27)* MSEK, an increase of 20% · · Total tests sold (repeat and initial) were 2.5 (2.0) million tests, an increase of 25% October – December 2014 · Net sales increased by 41% to 50 (36)* MSEK · Net sales for clinical use of NIOX products were 36 (26)* MSEK, an increase of 39% · Strategic sales were 13 (8)* MSEK, an increase of 57% · · Total tests sold (repeat and initial) were 0.7 (0.5) million tests, an increase of 40% *Note all numbers in ( ) are the corresponding period previous year and in the same unit. CEO’s Comments on Q4 2014 Sales “In terms of topline results, Q4 2014 represents the best fourth quarter in the Company’s history. Additionally, with strong consecutive quarters in Q2, Q3 and Q4, the YTD results represent the best full year sales performance ever. All areas of the business contributed to the success in Q4 and for the full year: Europe/RoW, U.S. Clinical, Strategic Sales, and Asia/Pacific. Our European/RoW business continues strong double digit growth with 27% growth for Q4 and 21% growth for the full year as compared to the corresponding periods in 2013. Growth for Q4 in the U.S. was 19% and for the full year was -2% as compared to the corresponding periods in 2013. Our US team demonstrated increased productivity as well as increased repeat test sales which is a key indicator of the underlying health of our business. Extensive change to the marketing and sales efforts early in the year resulted in lower sales in the first half of 2014. As previously communicated the productivity of the new sales model and all its attributes was anticipated to start materializing after Q2 and those results have been apparent in the second half of the year. The Asia Pacific region has exhibited exceptional performance with growth of 161% for Q4 and 164% for the full year, as compared to the corresponding periods in 2013, with Japan as a key contributor. With the re-registration of NIOX MINO in China, we expect to return to growth in that market but it will take some time to re-establish the selling cycle. Our consumable sales continue to grow in China. Strategic sales finished the year with a very strong performance driven by additional clinical studies starting up and commencement of shipments that had been delayed due to slow trial initiation. We are very pleased with the development of our sales performance during the year and believe we have a strong foundation for continued growth in the coming quarters" said Aerocrine's President and CEO, Scott Myers.” For further information, please contact: Scott Myers, President and CEO: +46 768 788 379 or +1 970 368 0336,or: Marshall Woodworth, CFO: +46 709 695 219 or + 1 919 749 8748 www.aerocrine.com or www.niox.com For case-studies on how FeNO assists in the daily practice to set correct diagnosis and initiate correct medication please visit: http://www.niox.com/en/ The information herein is published in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Trading Act. This information was submitted for publication on January 7, 2015, at 8.00 a.m.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quantum Space Joins $185M NASA Lunar Transport Deal

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Boston STEM Expo Sparks Young Minds in Engineering

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

TCL's Display Future: AI Meets Screens at DTC 2026

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...